243 related articles for article (PubMed ID: 27217700)
1. Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy.
Saeedi Saravi SS; Ghazi-Khansari M; Ejtemaei Mehr S; Nobakht M; Mousavi SE; Dehpour AR
World J Gastroenterol; 2016 May; 22(19):4685-94. PubMed ID: 27217700
[TBL] [Abstract][Full Text] [Related]
2. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats.
Ma Z; Miyamoto A; Lee SS
Gastroenterology; 1996 Apr; 110(4):1191-8. PubMed ID: 8613009
[TBL] [Abstract][Full Text] [Related]
3. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.
Liu H; Ma Z; Lee SS
Gastroenterology; 2000 May; 118(5):937-44. PubMed ID: 10784593
[TBL] [Abstract][Full Text] [Related]
4. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy.
Ma Z; Lee SS; Meddings JB
J Hepatol; 1997 Apr; 26(4):904-12. PubMed ID: 9126806
[TBL] [Abstract][Full Text] [Related]
5. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.
Gaskari SA; Liu H; Moezi L; Li Y; Baik SK; Lee SS
Br J Pharmacol; 2005 Oct; 146(3):315-23. PubMed ID: 16025138
[TBL] [Abstract][Full Text] [Related]
6. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy.
Jaue DN; Ma Z; Lee SS
Hepatology; 1997 Jun; 25(6):1361-5. PubMed ID: 9185753
[TBL] [Abstract][Full Text] [Related]
7. The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy.
Zavecz JH; Battarbee HD
Cardiovasc Toxicol; 2010 Jun; 10(2):117-29. PubMed ID: 20414815
[TBL] [Abstract][Full Text] [Related]
8. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat.
Liu H; Song D; Lee SS
Am J Physiol Gastrointest Liver Physiol; 2001 Jan; 280(1):G68-74. PubMed ID: 11123199
[TBL] [Abstract][Full Text] [Related]
9. Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.
Kim SY; Kim KH; Schilling JM; Leem J; Dhanani M; Head BP; Roth DM; Zemljic-Harpf AE; Patel HH
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G531-G541. PubMed ID: 31961720
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
Wang W; Yan J; Wang H; Shi M; Zhang M; Yang W; Peng C; Li H
PLoS One; 2014; 9(1):e83908. PubMed ID: 24404143
[TBL] [Abstract][Full Text] [Related]
11. Involvement of endogenous opioid peptides and nitric oxide in the blunted chronotropic and inotropic responses to beta-adrenergic stimulation in cirrhotic rats.
Ebrahimi F; Tavakoli S; Hajrasouliha AR; Sadeghipour H; Dehghani M; Ahmadi SH; Dehpour AR
Fundam Clin Pharmacol; 2006 Oct; 20(5):461-71. PubMed ID: 16968416
[TBL] [Abstract][Full Text] [Related]
12. An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats.
Ceolotto G; Papparella I; Sticca A; Bova S; Cavalli M; Cargnelli G; Semplicini A; Gatta A; Angeli P
Hepatology; 2008 Dec; 48(6):1913-23. PubMed ID: 19003918
[TBL] [Abstract][Full Text] [Related]
13. Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.
Dhingra R; Gang H; Wang Y; Biala AK; Aviv Y; Margulets V; Tee A; Kirshenbaum LA
Circ Heart Fail; 2013 Mar; 6(2):335-43. PubMed ID: 23395931
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy.
Yu SY; Liu L; Li P; Li J
Thorac Cardiovasc Surg; 2013 Apr; 61(3):223-8. PubMed ID: 22684415
[TBL] [Abstract][Full Text] [Related]
15. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
Bridle KR; Sobbe AL; de Guzman CE; Santrampurwala N; Jaskowski LA; Clouston AD; Campbell CM; Nathan Subramaniam V; Crawford DH
Liver Int; 2015 Apr; 35(4):1451-63. PubMed ID: 24517519
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the mTOR Pathway Exerts Cardioprotective Effects Partly through Autophagy in CLP Rats.
Han W; Wang H; Su L; Long Y; Cui N; Liu D
Mediators Inflamm; 2018; 2018():4798209. PubMed ID: 30050390
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Dysfunction in Cirrhotic Cardiomyopathy is Associated with Alterations of Phospholamban Phosphorylation and IL-6 Levels.
Gregolin CS; do Nascimento M; Borges de Souza SL; Ferreira Mota GA; Bomfim GF; de Azevedo Melo Luvizotto R; Sugizaki MM; Zanati Bazan SG; Salomé de Campos DH; Dias MC; Correa CR; Cicogna AC; Ferreira do Nascimento A
Arch Med Res; 2021 Apr; 52(3):284-293. PubMed ID: 33220932
[TBL] [Abstract][Full Text] [Related]
18. Activation of mammalian target of rapamycin induces lipid accumulation in the diaphragm of ventilated rats and hypoxia-treated C2C12 cells.
Yu T; Wang M; Wen Y; Cao Y; Shen G; Jiang X; Wu J; Lu W; Jin X
J Surg Res; 2018 May; 225():82-89. PubMed ID: 29605039
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy.
Ma Z; Zhang Y; Huet PM; Lee SS
J Hepatol; 1999 Mar; 30(3):485-91. PubMed ID: 10190733
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
